Format

Send to

Choose Destination
Br J Cancer. 2018 Feb 20;118(4):577-586. doi: 10.1038/bjc.2017.425. Epub 2017 Nov 30.

Tumour budding in oral squamous cell carcinoma: a meta-analysis.

Author information

1
Department of Patholosgy, University of Helsinki, Haartmaninkatu 3, PO Box 21, Helsinki FIN-00014, Finland.
2
Department of Oral and Maxillofacial Diseases, University of Helsinki, Haartmaninkatu 8, PO Box 63, Helsinki FI-00014, Finland.
3
Institute of Dentistry, University of Misurata, PO Box 2478, Misurata, Libya.
4
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki FIN-00014, Finland.
5
Helsinki Institute for Information Technology HIIT and Department of Mathematics and Statistics, University of Helsinki, Helsinki FIN-00014, Finland.
6
Department of Public Health, University of Helsinki, Helsinki FIN-00014, Finland.
7
Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Kasarminkatu 11-13, Helsinki FI-00130, Finland.
8
Helsinki University Hospital, Helsinki FIN-00014, Finland.
9
Research Group of Cancer Research and Translational Medicine, Medical Faculty, University of Oulu, PO Box 5281, Oulu 90014, Finland.
10
Medical Research Center, Oulu University Hospital, Oulu 90220, Finland.
11
Department of Pathology, University of Turku, Kiinamyllynkatu 10, Turku 20520, Finland.

Abstract

BACKGROUND:

Tumour budding has been reported as a promising prognostic marker in many cancers. This meta-analysis assessed the prognostic value of tumour budding in oral squamous cell carcinoma (OSCC).

METHODS:

We searched OvidMedline, PubMed, Scopus and Web of Science for articles that studied tumour budding in OSCC. We used reporting recommendations for tumour marker (REMARK) criteria to evaluate the quality of studies eligible for meta-analysis.

RESULTS:

A total of 16 studies evaluated the prognostic value of tumour budding in OSCC. The meta-analysis showed that tumour budding was significantly associated with lymph node metastasis (odds ratio=7.08, 95% CI=1.75-28.73), disease-free survival (hazard ratio=1.83, 95% CI=1.34-2.50) and overall survival (hazard ratio=1.88, 95% CI=1.25-2.82).

CONCLUSIONS:

Tumour budding is a simple and reliable prognostic marker for OSCC. Evaluation of tumour budding could facilitate personalised management of OSCC.

PMID:
29190636
PMCID:
PMC5830589
DOI:
10.1038/bjc.2017.425
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center